ArticleJournal of Korean medical science2026
Time Frame Analysis of Medical Device Approval, New Health Technology Assessment, and Reimbursement Decision-Making in Korea.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundThe time required for the health insurance listing, including health technology assessment (HTA) after medical device approval, has a significant impact on the medical device industry, clinical practice, and patient access to treatment. The aim of this study is to analyze the total time frame from device approval to health insurance listing via HTA and to examine the duration of each procedural step.
methodsUsing publicly available data, the study identified 34 medical technologies submitted for HTA and subsequently listed for health insurance coverage between 2021 and 2023. The study analyzed the time frame from device approval to health insurance listing, including evaluation periods for existing coverage category determination, HTA, and listing.
resultsThe median time from device approval to health insurance listing was 6.0 years for all technologies (n = 34) and 2.4 years for moderate- to high-risk or novel devices requiring pre-market approval (n = 15). For technologies that utilized the parallel review track (n = 8), the median time was 1.5 years. Median durations for existing coverage category determination, HTA, and health insurance listing for all technologies were 64.0, 244.5, and 346.0 days, respectively, and for moderate- to high-risk or novel devices, 65.0, 240.0, and 339.0 days, respectively.
conclusionThe process from device approval to health insurance listing in Korea takes a considerable amount of time. Streamlining evaluation and reimbursement processes is essential to accelerating patient access to novel treatments. To support the timely adoption of new technologies, policymakers should prioritize efficiency while maintaining safety and effectiveness standards.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.